Citigroup
CCCC icon

Citigroup’s C4 Therapeutics CCCC Stock Holding History

Citigroup’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,600
Closed -$41.8K – 5622
2024
Q4 		$41.8K Buy
+11,600
New +$57.7K ﹤0.01% 5133

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup's CCCC Position: Q2 2026 in Review

Citigroup increased its C4 Therapeutics (CCCC) stake by 16% in Q2 2026, buying an estimated $23.8K and bringing the position to 49,389 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #4267.

Citigroup first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $6.3M in Q1 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Citigroup held 49,389 shares of C4 Therapeutics worth $231K as of Q2 2026.
  • Citigroup bought 6,961 C4 Therapeutics shares in Q2 2026, an estimated $23.8K.
  • C4 Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4267 holding.
  • Citigroup first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Citigroup's C4 Therapeutics position peaked at $6.3M in Q1 2024.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.